Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Endorectal MR imaging of prostate cancer: Evaluation of tumor capsular contact length as a sign of extracapsular extension.

Mendez G, Foster BR, Li X, Shannon J, Garzotto M, Amling CL, Coakley FV.

Clin Imaging. 2018 Jul - Aug;50:280-285. doi: 10.1016/j.clinimag.2018.04.020. Epub 2018 Apr 25.

PMID:
29727817
2.

Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database.

Kapadia AA, Martinez Acevedo A, Liu JJ, Garzotto M, Conlin M, Amling C, Kopp RP.

J Urol. 2018 Sep;200(3):535-540. doi: 10.1016/j.juro.2018.03.075. Epub 2018 Mar 15.

PMID:
29551404
3.

Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.

Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, Berse B, Kemeter MJ, Febbo PG, Dash A.

Am J Manag Care. 2018 Jan;24(1 Suppl):S4-S10.

4.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI.

Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10.

5.

Is Low-Risk Prostate Cancer More Indolent in Younger Patients?

Garzotto M.

J Clin Oncol. 2017 Jun 10;35(17):1870-1871. doi: 10.1200/JCO.2017.72.3684. Epub 2017 Mar 27. No abstract available.

PMID:
28346807
6.

Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial.

Zhang Z, Garzotto M, Beer TM, Thuillier P, Lieberman S, Mori M, Stoller WA, Farris PE, Shannon J.

Nutr Cancer. 2016 Nov-Dec;68(8):1309-1319. Epub 2016 Sep 20.

7.

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.

Bergstrom CP, Ruffell B, Ho CM, Higano CS, Ellis WJ, Garzotto M, Beer TM, Graff JN.

Anticancer Drugs. 2017 Jan;28(1):120-126.

PMID:
27669423
8.

Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.

Flamiatos JF, Beer TM, Graff JN, Eilers KM, Tian W, Sekhon HS, Garzotto M.

BJU Int. 2017 May;119(5):709-716. doi: 10.1111/bju.13612. Epub 2016 Aug 23.

9.

Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling.

Li X, Cai Y, Moloney B, Chen Y, Huang W, Woods M, Coakley FV, Rooney WD, Garzotto MG, Springer CS Jr.

J Magn Reson. 2016 Aug;269:104-112. doi: 10.1016/j.jmr.2016.05.018. Epub 2016 May 28.

10.

Gene-expression profiling of localized prostate cancer: still miles to go before we sleep.

Garzotto M, Kopp RP.

Future Oncol. 2016 Feb;12(3):273-6. doi: 10.2217/fon.15.316. Epub 2016 Jan 19. No abstract available.

11.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI.

Int J Cancer. 2015 Apr 15;136(8):1856-62. doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

12.

Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS.

PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014.

13.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

14.

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM.

Clin Cancer Res. 2014 Mar 1;20(5):1306-12. doi: 10.1158/1078-0432.CCR-13-1775. Epub 2013 Dec 18.

15.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.

Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.

16.

Agent Orange as a risk factor for high-grade prostate cancer.

Ansbaugh N, Shannon J, Mori M, Farris PE, Garzotto M.

Cancer. 2013 Jul 1;119(13):2399-404. doi: 10.1002/cncr.27941. Epub 2013 May 13.

17.

Advances in the multimodality management of high-risk prostate cancer.

Garzotto M, Hung AY.

Surg Oncol Clin N Am. 2013 Apr;22(2):375-94. doi: 10.1016/j.soc.2012.12.012. Epub 2013 Jan 18. Review.

PMID:
23453341
18.

Benign prostatic hyperplasia: a brief overview of pathogenesis, diagnosis, and therapy.

Priest R, Garzotto M, Kaufman J.

Tech Vasc Interv Radiol. 2012 Dec;15(4):261-4. doi: 10.1053/j.tvir.2012.10.001. Review.

PMID:
23244721
19.

Cell membrane water exchange effects in prostate DCE-MRI.

Li X, Priest RA, Woodward WJ, Siddiqui F, Beer TM, Garzotto MG, Rooney WD, Springer CS Jr.

J Magn Reson. 2012 May;218:77-85. doi: 10.1016/j.jmr.2012.03.019. Epub 2012 Mar 28.

20.

Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection.

Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto MG, Springer CS Jr.

Magn Reson Med. 2013 Jan;69(1):171-8. doi: 10.1002/mrm.24211. Epub 2012 Mar 27.

21.

Androgen deprivation therapy for prostate cancer: not so simple.

Tadros NN, Garzotto M.

Asian J Androl. 2011 Mar;13(2):187-8. doi: 10.1038/aja.2010.174. Epub 2011 Jan 31. No abstract available.

22.

Benign Prostatic Hyperplasia (BPH) Management in Primary Care: Screening and Therapy [Internet].

Helfand M, Muzyk T, Garzotto M.

Washington (DC): Department of Veterans Affairs (US); 2007 Feb.

23.

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N.

Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.

24.

Erythrocyte fatty acids and prostate cancer risk: a comparison of methods.

Shannon J, O'Malley J, Mori M, Garzotto M, Palma AJ, King IB.

Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):161-9. doi: 10.1016/j.plefa.2010.06.003. Epub 2010 Jul 14.

25.

Editorial comment.

Garzotto M.

J Urol. 2010 Aug;184(2):500. doi: 10.1016/j.juro.2010.03.168. Epub 2010 Jun 17. No abstract available.

PMID:
20620407
26.

Minimal benefit of an endorectal balloon for prostate immobilization as verified by daily localization.

Hung AY, Garzotto M, Kaurin D.

Med Dosim. 2011 Summer;36(2):195-9. doi: 10.1016/j.meddos.2010.03.003. Epub 2010 May 26.

PMID:
20537888
27.

Acupuncture for hot flashes in patients with prostate cancer.

Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C, Eilers K.

Urology. 2010 Nov;76(5):1182-8. doi: 10.1016/j.urology.2010.03.033. Epub 2010 May 21.

28.

Contemporary management of high-risk localized prostate cancer.

Garzotto M, Hung AY.

Curr Urol Rep. 2010 May;11(3):159-64. doi: 10.1007/s11934-010-0101-0. Review.

PMID:
20425622
29.

ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ.

Cancer Res. 2010 Apr 15;70(8):3239-48. doi: 10.1158/0008-5472.CAN-09-3186. Epub 2010 Apr 13.

30.

Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

O'Brien C, True LD, Higano CS, Rademacher BL, Garzotto M, Beer TM.

Am J Clin Pathol. 2010 Apr;133(4):654-61. doi: 10.1309/AJCP8EL5FTZSOBIH.

31.

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM.

Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/cncr.24960.

32.

Editorial comment.

Garzotto M.

J Urol. 2010 Jan;183(1):123-4; discussion 125. doi: 10.1016/j.juro.2009.08.216. No abstract available.

PMID:
19913241
33.

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.

Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077.

34.

Folate intake and prostate cancer risk: a case-control study.

Shannon J, Phoutrides E, Palma A, Farris P, Peters L, Forester A, Tillotson CJ, Garzotto M.

Nutr Cancer. 2009;61(5):617-28. doi: 10.1080/01635580902846593.

PMID:
19838935
35.

Prostate cancer-associated gene expression alterations determined from needle biopsies.

Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM.

Clin Cancer Res. 2009 May 1;15(9):3135-42. doi: 10.1158/1078-0432.CCR-08-1982. Epub 2009 Apr 14.

36.

Lower urinary tract symptoms increase the risk of falls in older men.

Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, Barrett-Connor E, Marshall LM.

BJU Int. 2009 Jul;104(1):63-8. doi: 10.1111/j.1464-410X.2008.08317.x. Epub 2009 Jan 19.

37.

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.

Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW.

BJU Int. 2008 Dec;102(11):1601-6. doi: 10.1111/j.1464-410X.2008.08017.x. Epub 2008 Sep 8.

38.

Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer.

Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW.

Urology. 2008 Sep;72(3):474-80. doi: 10.1016/j.urology.2008.02.050. Epub 2008 Apr 14. Review. No abstract available.

PMID:
18407333
39.
40.
41.

Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

Spurgeon SE, Mongoue-Tchokote S, Collins L, Priest R, Hsieh YC, Peters LM, Beer TM, Mori M, Garzotto M.

Urology. 2007 May;69(5):931-5.

PMID:
17482937
42.
43.

Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?

Lycette JL, Bland LB, Garzotto M, Beer TM.

Clin Genitourin Cancer. 2006 Dec;5(3):198-205. Review.

PMID:
17239273
44.

Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.

Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL.

Cancer Chemother Pharmacol. 2007 Apr;59(5):581-7. Epub 2006 Oct 26.

PMID:
17066293
45.

Metastatic adenocarcinoma of prostate in a healing sternotomy site.

Adams G, Mitchell A, Ravichandran R, Beer TM, Garzotto M.

Urology. 2006 Jul;68(1):204.e13-5.

PMID:
16808964
46.

Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.

Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3444-51.

47.

Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.

Garzotto M, Myrthue A, Higano CS, Beer TM.

Urol Oncol. 2006 May-Jun;24(3):254-9.

PMID:
16678060
48.

Effect of calcitriol on prostate-specific antigen in vitro and in humans.

Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K.

Clin Cancer Res. 2006 May 1;12(9):2812-6.

49.

Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy.

Spurgeon SE, Hsieh YC, Rivadinera A, Beer TM, Mori M, Garzotto M.

J Urol. 2006 Mar;175(3 Pt 1):918-22.

PMID:
16469580
50.

Testosterone loss and estradiol administration modify memory in men.

Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS.

J Urol. 2006 Jan;175(1):130-5.

PMID:
16406889

Supplemental Content

Loading ...
Support Center